Press Enter to search · Esc to close
New real-world data is shifting the GLP-1 conversation from 'does it work' to 'how to use it without getting hurt.' Here's what the latest evidence actually says.
AstraZeneca's once-daily small molecule posts placebo-controlled weight-loss data in The Lancet — and hints at a future where the obesity revolution doesn't require a needle.
Two new trials in The Lancet put the first credible oral, non-peptide GLP-1 drugs on the runway — a shift that could change who actually gets access to this class.
A new narrative review pulls together population data from five continents and finds the liver behaves very differently depending on your hormones, your fat distribution, and your decade of life.
A 23,000-adult Chinese study suggests high-sensitivity CRP, a routine inflammation marker, tracks who slides into — and out of — metabolic syndrome. For parents juggling everything, it may be a useful early signal.
A new analysis of more than 7,500 older adults suggests very high HDL — long sold as the 'good' cholesterol — may track with lower cognitive scores. Here's what tired parents need to know about their own labs (and their parents' labs).
A new post-hoc analysis tracks inflammatory and immune markers in adults with type 2 diabetes for two years on a carb-restricted, ketogenic plan — and the signal goes well beyond blood sugar.
Endocrinologists are quietly rewriting the rulebook — treating diabetes, fatty liver, and heart disease as one slow-burning inflammatory story. Here's what that means for the rest of us.
A new mouse study reframes the molecule behind your burning legs as a messenger, not a metabolic leftover — and hints at why intense training keeps outperforming easy cardio on the metrics that matter.
GLP-1s deliver durable fat loss and metabolic wins — but a maturing evidence base is also flagging ocular signals and structural changes worth knowing before you pin or pass.